<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1012-2966</journal-id>
<journal-title><![CDATA[Gaceta Médica Boliviana]]></journal-title>
<abbrev-journal-title><![CDATA[Gac Med Bol]]></abbrev-journal-title>
<issn>1012-2966</issn>
<publisher>
<publisher-name><![CDATA[Facultad de Medicina de la Universidad Mayor de San Simón]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1012-29662021000200187</article-id>
<article-id pub-id-type="doi">10.47993/gmb.v44i2.350</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evaluación de la Ivermectina más Anticoagulación versus Anticoagulación en Pacientes Críticos no Ventilados, con COVID-19: Ensayo Clínico Multicentrico en Cochabamba, Bolivia]]></article-title>
<article-title xml:lang="en"><![CDATA[Evaluation of Ivermectin plus Anticoagulation vs Anticoagulation in Critical non-Ventilated Patients with COVID-19: Multicenter Clinical trial in Cochabamba, Bolivia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ortega Martinez]]></surname>
<given-names><![CDATA[Rommer Alex]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carpio Deheza]]></surname>
<given-names><![CDATA[Gonzalo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Privada del Valle  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Bolivia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Univalle  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2021</year>
</pub-date>
<volume>44</volume>
<numero>2</numero>
<fpage>187</fpage>
<lpage>197</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_arttext&amp;pid=S1012-29662021000200187&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_abstract&amp;pid=S1012-29662021000200187&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_pdf&amp;pid=S1012-29662021000200187&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  La falta de drogas contra el COVID-19 y la crisis sanitaria respaldaron para evaluar la ivermectina mas anticoagulación (ANCO) versus ANCO en pacientes críticos no ventilados con COVID-19, y efecto en la clínica, complicaciones y sobrevida.  Objetivos:  evaluar la ivermectina vs la anticoagulación en los pacientes críticos con COVID-19 no ventilados, y su efecto en la clínica del paciente, parámetros laboratoriales, evolución y complicaciones en Hospitales de 2do y 3er nivel (Hospital Sud y Hospital Obrero Nro. 2 de la Caja Nacional de Salud-CNS), gestión 2020-2021.  Material y métodos:  ensayo clínico, aleatorizado; julio 2020 a enero 2021, rama con ivermectina (0,2 mg/k) + ANCO y otra ANCO; con dos grupos de variables y tres evaluaciones.  Resultados:  44 pacientes inscritos, 27 al Hospital Sud y 17 CNS; 64% al grupo de ivermectina+ANCO, 57% sexo masculino. Media de edad 57,3 años; de hospitalización 13 días; obesidad 40%; posibilidad de recuperación con ivermectina 10 días y ANCO &gt; de 20 días. La media de la saturación de oxigeno inicial (SatO2) 79% (PaO2/FiO2=60) en el grupo con ivermectina+ ANCO y 75% (55) en el grupo ANCO; en una medición final 86% (138) y 83% (120) respectivamente. La primera evaluación, mostro Rho Spearman=-0,7 entre SatO2 y frecuencia respiratoria (FR) y un Rho=-0,7 entre pH y FiO2 en la tercera evaluación. Sobrevida de 26 días, RR=0,98, IC 95% (0,49-1,98), sin diferencias en ambas ramas (p=0,94); 27% intubados con ivermectina+ANCO y 21% ANCO; &gt;60% ingresaron a la terapia intensiva; probabilidad de necesitar Intubación, con RR de 0,76, IC 95% (0,42-1,40), (p=0,4).  Conclusiones:  Ivermectina no reduce la mortalidad ni posibilidad de intubación. Evolución depende de gravedad, si están polimedicados, días de progresión y uso de oxígeno. Es necesario estandarizar combinaciones, dosis, muestras grandes y homogéneas; por el momento no podemos recomendar el uso de la ivermectina.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  The lack of drugs against COVID-19 and the health crisis prompted to evaluate ivermectin plus anticoagulation (ANCO) versus ANCO in non-ventilated critically ill patients with COVID-19, and the effect on clinical outcome, complications and survival.  Objectives:  To evaluate ivermectin vs anticoagulation in non-ventilated critical patients with COVID-19, and its effect on the patient's clinical condition, laboratory parameters, evolution and complications in 2nd and 3rd level hospitals (Hospital Sud and Hospital Obrero No. 2 of the Caja Nacional de Salud-CNS).  Material and methods:  Randomized clinical trial, from July 2020 to January 2021, ivermectin (0.2 mg/k) + ANCO arm and ANCO arm; with two variable groups and three assessments. Results: 44 patients enrolled, 27 at Hospital Sud and 17 CNS; 64% to the ivermectin+ANCO group, 57% male. Average age 57.3 years; of hospitalization 13 days; obesity 40%; possibility of recovery with ivermectin 10 days and ANCO&gt; 20 days. The mean initial oxygen saturation (SatO2) 79% (PaO2/FiO2=60) in the group with ivermectin + ANCO and 75% (55) in the ANCO group; in a final measurement 86% (138) and 83% (120) respectively. The first evaluation showed Rho Spearman=-0.7 between SatO2 and respiratory rate (FR) and a Rho=-0.7 between pH and FiO2 in the third evaluation. 26-day survival, RR = 0.98, 95% CI (0.49-1.98), with no differences in both arms (p = 0.94); 27% intubated with ivermectin + ANCO and 21% ANCO; &gt;60% were admitted to intensive care; probability of needing intubation, with RR of 0.76, 95% CI (0.42-1.40), (p = 0.4).  Conclusions:  Ivermectin does not reduce mortality or possibility of intubation. Evolution depends on severity, whether patients are polymedicated, days of progression and use of oxygen. It is necessary to standardise combinations, doses, large and homogeneous samples; for the moment we cannot recommend the use of ivermectin.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[efectividad]]></kwd>
<kwd lng="es"><![CDATA[ivermectina]]></kwd>
<kwd lng="es"><![CDATA[anticoagulantes]]></kwd>
<kwd lng="es"><![CDATA[COVID-19]]></kwd>
<kwd lng="en"><![CDATA[effectiveness]]></kwd>
<kwd lng="en"><![CDATA[ivermectin]]></kwd>
<kwd lng="en"><![CDATA[anticoagulants]]></kwd>
<kwd lng="en"><![CDATA[COVID-19]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ventura-Garcia]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Roura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pell]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Posada]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gascón]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Aldasoro]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Socio-Cultural Aspects of Chagas Disease: A Systematic Review of Qualitative Research]]></article-title>
<source><![CDATA[PLoS Negl Trop Dis]]></source>
<year>2013</year>
<volume>7</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goffman]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Stigma: notes on the management of spoiled identity]]></source>
<year>1963</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Penguin Books]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weiss]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stigma and the social burden of neglected tropical diseases]]></article-title>
<source><![CDATA[PLoS Negl Trop Dis]]></source>
<year>2008</year>
<volume>2</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stangl]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Earnshaw]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Logie]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Van Brakel]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Simbayi]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Barré]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Health Stigma and Discrimination Framework A global, crosscutting framework to inform research, intervention development, and policy on health-related stigmas]]></article-title>
<source><![CDATA[BMC Med]]></source>
<year>2019</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>18-23</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hofstraat]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Van Brakel]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Social stigma towards neglected tropical diseases A systematic review]]></article-title>
<source><![CDATA[Int Health]]></source>
<year>2015</year>
<volume>8</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>i53-70</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mwelecele Ntuli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 2021-2030]]></source>
<year>2021</year>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gascon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bern]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pinazo]]></surname>
<given-names><![CDATA[M-J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chagas disease in Spain, the United States and other non-endemic countries]]></article-title>
<source><![CDATA[Acta Tropica]]></source>
<year>2010</year>
<volume>115</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>22-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torrico]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gascon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso-Vega]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pinazo]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Schijman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens a proof-of-concept, randomised, placebo-controlled trial]]></article-title>
<source><![CDATA[Lancet Infect Dis]]></source>
<year>2018</year>
<volume>18</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>419-30</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moriana]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz G]]></surname>
<given-names><![CDATA[Fanjul G]]></given-names>
</name>
</person-group>
<source><![CDATA[Rompiendo el silencio. Una oportunidad para los pacientes de Chagas]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alonso-Padilla]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cortés-Serra]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Pinazo]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bottazzi]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Abril]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Barreira]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America]]></article-title>
<source><![CDATA[Expert Rev Anti Infect Ther]]></source>
<year>2019</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>145-57</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Forsyth]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Meymandi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Moss]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Cone]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Batista]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Proposed multidimensional framework for understanding Chagas disease healthcare barriers in the United States]]></article-title>
<source><![CDATA[PLoS Negl Trop Dis]]></source>
<year>2019</year>
<volume>13</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1-23</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinazo]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pinto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Saravia]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A strategy for scaling up access to comprehensive care in adults with Chagas disease in endemic countries The Bolivian Chagas Platform]]></article-title>
<source><![CDATA[PLoS Negl Trop Dis]]></source>
<year>2017</year>
<volume>11</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urias]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Vogels]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Yalcin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Malagrida]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Steinhaus]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Zweekhorst]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A framework for Science Shop processes Results of a modified Delphi study]]></article-title>
<source><![CDATA[Futures]]></source>
<year>2020</year>
<volume>123</volume>
<numero>2020</numero>
<issue>2020</issue>
<page-range>102613</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jimeno]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Mendoza]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Zapana]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[de la Torre]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Torrico]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lozano]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Social determinants in the access to health care for Chagas disease: A qualitative research on family life in the "Valle Alto" of Cochabamba, Bolivia]]></article-title>
<source><![CDATA[PLOS ONE]]></source>
<year>2021</year>
<volume>16</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanmartino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hacer Frente A La Enfermedad De Chagas Partiendo De Las Concepciones De Las Poblaciones Afectadas]]></article-title>
<source><![CDATA[Prax Educ]]></source>
<year>2006</year>
<numero>10</numero>
<issue>10</issue>
<page-range>104-5</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pereira Silva]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Chagas: registro de histórias de vida e atividades de educação não formal com portadores de Doença de Chagas TT - Living with Chagas: recording life histories and non-formal education activities with Chagas Disease patients]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Rio de Janeiro ]]></publisher-loc>
<publisher-name><![CDATA[Instituto Oswaldo Cruz]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<collab>Oliveira Jr W de</collab>
<article-title xml:lang=""><![CDATA[All-around care for patients with Chagas disease a challenge for the XXI century]]></article-title>
<source><![CDATA[Mem Inst Oswaldo Cruz]]></source>
<year>2009</year>
<volume>104</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>181-6</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Briceño-León]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Galván]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The social determinants of Chagas disease and the transformations of Latin America]]></article-title>
<source><![CDATA[Mem Inst Oswaldo Cruz]]></source>
<year>2007</year>
<volume>102</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>109-12</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Forsyth]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA["I Cannot Be Worried": Living with Chagas Disease in Tropical Bolivia]]></article-title>
<source><![CDATA[PLoS Negl Trop Dis]]></source>
<year>2017</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-14</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tong]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sainsbury]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Craig]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consolidated criteria for reporting qualitative research (COREQ) A 32-item checklist for interviews and focus groups]]></article-title>
<source><![CDATA[Int J Qual Heal Care]]></source>
<year>2007</year>
<volume>19</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>349-57</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ozaki]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quality of life and depressive symptoms in Chagas disease patients]]></article-title>
<source><![CDATA[Qual life Res]]></source>
<year>2011</year>
<volume>20</volume>
<page-range>133-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[van Wijk]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[van Selm]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barbosa]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Parisi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stigma, participation restriction and mental distress in patients affected by leprosy, cutaneous leishmaniasis and Chagas disease a pilot study in two co-endemic regions of eastern Colombia]]></article-title>
<source><![CDATA[Trans R Soc Trop Med Hyg]]></source>
<year>2020</year>
<volume>114</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>476-82</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinazo]]></surname>
<given-names><![CDATA[M-J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The importance of multidisciplinary approach to deal with the new epidemiological scenario of Chagas disease]]></article-title>
<source><![CDATA[Acta Trop]]></source>
<year>2015</year>
<volume>151</volume>
<page-range>16-20</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanmartino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Forsyth]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Avaria]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Velarde-Rodriguez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez I Prat]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Albajar-Viñas]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The multidimensional comprehension of chagas disease. Contributions, approaches, challenges and opportunities from and beyond the information, education and communication field]]></article-title>
<source><![CDATA[Mem Inst Oswaldo Cruz]]></source>
<year>2021</year>
<volume>116</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pardo Flores]]></surname>
<given-names><![CDATA[EW]]></given-names>
</name>
<name>
<surname><![CDATA[Billot]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mendoza Claure]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Claros Zanabria]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Torrico]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lozano Beltrán]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Implementación de un modelo de comunicación en Chagas basado en la estrategia de educación por pares]]></article-title>
<source><![CDATA[Gac Medica Boliv]]></source>
<year>2020</year>
<volume>42</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>117-21</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hasslocher-Moreno]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Saraiva]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Sangenis]]></surname>
<given-names><![CDATA[LHC]]></given-names>
</name>
<name>
<surname><![CDATA[Xavier]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[de Sousa]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study]]></article-title>
<source><![CDATA[E Clinical Medicine]]></source>
<year>2021</year>
<volume>31</volume>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murcia]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Simón]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Carrilero]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Roig]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Segovia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of infected women of childbearing age prevents congenital trypanosoma cruzi infection by eliminating the parasitemia detected by PCR]]></article-title>
<source><![CDATA[J Infect Dis]]></source>
<year>2017</year>
<volume>215</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1452-8</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinazo]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pereiro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Herazo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chopita]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Forsyth]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lenardón]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interventions to bring comprehensive care to people with Chagas disease: Experiences in Bolivia, Argentina and Colombia]]></article-title>
<source><![CDATA[Acta Trop]]></source>
<year>2020</year>
<volume>203</volume>
<numero>2019</numero>
<issue>2019</issue>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sosa-Estani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Segura]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Integrated control of chagas disease for its elimination as a public health problem - A review]]></article-title>
<source><![CDATA[Mem Inst Oswaldo Cruz]]></source>
<year>2015</year>
<volume>110</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>289-98</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
